TY  - GEN
AU  - Chew,D P
AU  - Bhatt,D L
AU  - Lincoff,A M
AU  - Moliterno,D J
AU  - Brener,S J
AU  - Wolski,K E
AU  - Topol,E J
TI  - Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials
SN  - 1524-4539
PY  - 2001///0614
KW  - Abciximab
KW  - Angioplasty, Balloon, Coronary
KW  - adverse effects
KW  - Antibodies, Monoclonal
KW  - therapeutic use
KW  - Coronary Disease
KW  - complications
KW  - Demography
KW  - Diabetes Complications
KW  - Dose-Response Relationship, Drug
KW  - Drug Therapy, Combination
KW  - Hemorrhage
KW  - etiology
KW  - Heparin
KW  - Humans
KW  - Immunoglobulin Fab Fragments
KW  - Incidence
KW  - Middle Aged
KW  - Randomized Controlled Trials as Topic
KW  - statistics & numerical data
KW  - Risk Assessment
KW  - Risk Factors
KW  - Thrombosis
KW  - Treatment Outcome
KW  - Whole Blood Coagulation Time
N1  - Publication Type: Journal Article; Meta-Analysis
UR  - https://doi.org/10.1161/01.cir.103.7.961
ER  -